Skip to main content
Premium Trial:

Request an Annual Quote

Arcturus Names TTR Amyloidosis as First Pipeline Program


RNAi startup Arcturus Therapeutics this week named transthyretin-mediated amyloidosis as the first indication to be added to its pipeline.

The disease is caused by mutations in the TTR gene, which triggers accumulation of abnormal amyloid proteins in the body. Notably, Alnylam Pharmaceuticals has been developing its own drugs for the disease, with an intravenously delivered one in phase III testing and a subcutaneously administered one in phase II.

Arcturus, however, uses proprietary siRNA-modification and drug-delivery technologies. Specifically, the company is developing drugs that incorporate unlocked nucleobase analog modifications — a technology acquired from Marina Biotech — and novel lipid nanoparticle carriers.

Arcturus said that in non-human primate testing, its UNA molecules treatment led to a greater than 75 percent knockdown of serum levels of the TTR protein after 10 days at a dose of 0.3 mg/kg. The effect, it added, lasted over three weeks with no adverse events associated with the delivery vehicles.

Rat toxicology studies, meanwhile, showed no incidence of adverse effects associated with multiple doses of Arcturus' RNAi compound, which was administered intravenously three times at 10 mg/kg over 15 days.

"Serum levels of the alanine aminotransferase and aspartate aminotransferase were determined after intravenous administration and no changes in these liver enzymes were observed," the firm said.

Arcturus CSO and COO Pad Chivukula said that the company expects to select a clinical candidate this year and enter phase I testing by early 2015, in line with previous guidance.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.